Encyclopedia of Malaria

Living Edition
| Editors: Peter G. Kremsner, Sanjeev Krishna

Glucose-6-Phosphate Dehydrogenase Deficiency and Primaquine Hemolytic Toxicity

  • J. Kevin Baird
  • Ari W. Satyagraha
  • Germana Bancone
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-8757-9_102-1



Primaquine as an oxidative drug can produce lethal side effect in G6PD-deficient individual.

Clinical and Public Health Importance

Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is a vitally important problem in malaria treatment, control, and elimination. It is the most common genetic disorder in humans, affecting about 400 million people (Beutler 1994). In populations living where malaria is endemic, the prevalence of the defect averages about 8 % (Howes 2012), very probably because G6PDd provides a survival advantage against the infection (Clark et al. 2009) as shown in Fig. 1. G6PDd exhibits enormous diversity, both in terms of residual enzyme activity phenotype (spanning from <1 % to 150 %) and underlying genotypes (many dozens of clinically significant mutants are known) (Minucci 2012). Mutations occur all along the length of this very large...


Residual Enzyme Activity G6PD Activity Cytochemical Staining Hemizygous Male Hexose Monophosphate Shunt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Abeyaratne KP, Halpe NL. Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phophate dehydrogenase. Ceylon Med J. 1968;27:134–8.Google Scholar
  2. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. Mitigation of the hemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. A preliminary report. Bull WHO. 1960;22:621–9.Google Scholar
  3. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol. 2012;80:151–201.PubMedCrossRefGoogle Scholar
  4. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36–57.PubMedCentralPubMedCrossRefGoogle Scholar
  5. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;37:1659–67.CrossRefGoogle Scholar
  6. Baird JK, Davidson Jr DE, Decker-Jackson JE. Oxidative activity of hydroxylated primaquine analogs. Non-toxicity to glucose-6-phosphate dehydrogenase-deficient human red blood cells in vitro. Biochem Pharmacol. 1986;35:1091–8.PubMedCrossRefGoogle Scholar
  7. Bangchang KN, Songsaeng W, Thanavibul A, Choroenlarp P, Karbwang J. Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. Trans R Soc Trop Med Hyg. 1994;88:220–2.PubMedCrossRefGoogle Scholar
  8. Beutler E. G6PD deficiency. Blood. 1994;84:3613–36.PubMedGoogle Scholar
  9. Beutler E, Mitchell M. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood. 1968;32:816–8.PubMedGoogle Scholar
  10. Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. Br J Haematol. 1977;35:331–40.PubMedCrossRefGoogle Scholar
  11. Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol. 1979;43:465–7.PubMedCrossRefGoogle Scholar
  12. Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood. 1989;74:2550–5.PubMedGoogle Scholar
  13. Brewer GJ, Zarafonetis CJ. The haemolytic effect of various regimens of primaquine and chloroquine in American negroes with G6PD deficiency and the lack of an effect of various antimalarial suppressive agents on erythrocyte metabolism. Bull WHO. 1967;36:303–8.PubMedCentralPubMedGoogle Scholar
  14. Brewer GJ, Tarlove AR, Alving AS. Methaemoglobin reduction test: a new, simple, in vitro test for identifying primaquine-sensitivity. Bull World Health Organ. 1960;22:633–40.PubMedCentralPubMedGoogle Scholar
  15. Bruekner RP, Ohrt C, Baird JK, Milhous WK. 8-aminoquinolines, chapter 7. In: Rosenthal PJ, editor. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. New Jersey: Humana Press; 2001.Google Scholar
  16. Charoenlarp P, Areekul S, Harinasuta T, Sirivorasarn P. The haemolytic effect of a single dose of 45mg of primaquine in G6PD-deficient Thais. J Med Assoc Thail. 1972;55:631–8.Google Scholar
  17. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, Richardson A, Teo YY, Small KK, Wilson J, Jallow M, Sisay-Joof F, Pinder M, Sabeti P, Kwiatkowski DP, Rockett KA. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Human Genet. 2009;17:1080–5.CrossRefGoogle Scholar
  18. Cost FT, Lopes SC, Albrecht L, Ataide R, Siqueira AM, Souza RM, Russell B, Renia L, Marinho CR, Lacerda MV. On the pathogenesis of Plasmodium vivax malaria: perspectives from the Brazilian field. Int J Parasitol. 2012;42:1099–105.CrossRefGoogle Scholar
  19. De Niz M, Eziefula AC, Othieno L, Mbabazi E, Nabukeera D, Ssemmondo E, Gonahasa S, Tumwebaze P, Diliberto D, Maiteki-Sebuguzi C, Staedke SG, Drakeley C. Tools for mass screening of G6PD deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in Uganda. Malar J. 2013;12:210.PubMedCentralPubMedCrossRefGoogle Scholar
  20. Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine. II. The natural course of hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med. 1954;44:171–6.PubMedGoogle Scholar
  21. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI. G6PD deficiency prevalence estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.PubMedCentralPubMedCrossRefGoogle Scholar
  22. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, Nhem S, Bouchier C, Tichit M, Christophel E, Taylor WR, Baird JK, Menard D. Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One. 2011;6(12):e28357.PubMedCentralPubMedCrossRefGoogle Scholar
  23. Kuwahata M, Wijesinghe R, Ho MF, Pelecanos A, Bobogare A, Landry L, Bugora H, Vallely A, McCarthy J. Population screening for glucose-6-phosphate dehydrogenase deficiencies in Isabel Province, Solomon Islands, using a modified enzyme assay on filter paper dried bloodspots. Malar J. 2010;9:223.PubMedCentralPubMedCrossRefGoogle Scholar
  24. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siquiera AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fenandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax: to what extent does this parasite kill? Clin Infect Dis. 2012;55:e67–74.PubMedCrossRefGoogle Scholar
  25. Marks AP, Gross RT. Erythrocyte G6PD-deficiency: evidence of differences between Negroes and Caucasians with respect to this genetically determined trait. J Clin Invest. 1959;38:2253–62.PubMedCentralPubMedCrossRefGoogle Scholar
  26. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations. Blood Cells Mol Dis. 2012a;48:154–65.PubMedCrossRefGoogle Scholar
  27. Minucci A, Gentile L, Zuppi C, Giardina B, Capoluongo E. Rapid and simple identification of the commonest glucose-6-phosphate dehydrogenase (G6PD) Italian mutations: from DNA extraction to genotyping. Clin Chim Acta. 2012b;14:1018–9.CrossRefGoogle Scholar
  28. Modiano G, Battistuzzi G, Esan GJ, Testa U, Luzzatto L. Genetic heterogeneity of “normal” human erythrocyte glucose-6-phosphate dehydrogenase: an isoelectrophoretic polymorphism. Proc Natl Acad Sci U S A. 1979;76(2):852–6.PubMedCentralPubMedCrossRefGoogle Scholar
  29. Pan M, Lin M, Yang L, Wu J, Zhan X, Zhao Y, Wen Y, Liu G, Yang L, Cai Y. Glucse-6-phosphate dehydrogenase (G6PD) gene mutations detection by improved high resolution DNA melting assay. Mol Biol Rep. 2013;40:3073–82.PubMedCrossRefGoogle Scholar
  30. Pannacciulli I, Tizianello A, Ajmar F, Salvidio E. The course of experimentally induced hemolytic anemia in a primaquine-sensitive Caucasian. A case study. Blood. 1965;25:92–5.PubMedGoogle Scholar
  31. Ramos Jr WM, Sardihna JF, Costa MR, Santana MS, Alecrim MG, Lacerda MV. Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon. Braz J Infect Dis. 2010;14:410–2.CrossRefGoogle Scholar
  32. Salvidio E, Pannacciulli I, Tizianello A, Ajmar F. Nature of hemolytic crises and the fate of G6PD-deficient, drug-damaged erythrocytes in Sardinians. New Engl J Med. 1967;276:1339–44.PubMedCrossRefGoogle Scholar
  33. Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, Wellems TE, Fairhurst RM. A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. Sci Rep. 2012;2:299.PubMedCentralPubMedCrossRefGoogle Scholar
  34. Tantular IS, Kawamoto F. An improved, simple screening method for detection of glucose-6-phosphate dehydrogenase deficiency. Trop Med Int Health. 2003;8:569–74.PubMedCrossRefGoogle Scholar
  35. Tantular IS, Iwai K, Lin K, Basuki S, Horie T, Htay HH, Matsuoka H, Marwoto H, Wongsrichanalai C, Dachlan YP, Kojima S, Ishii A, Kawamoto F. Field trials of a rapid test for G6PD deficiency in combination with a rapid diagnosis of malaria. Trop Med Int Health. 1999;4:245–50.PubMedCrossRefGoogle Scholar
  36. Tinley KE, Loughlin AM, Jepson A, Barnett ED. Evaluation of a rapid qualitative enzyme chromatographic test for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2010;82(2):210–4.PubMedCentralPubMedCrossRefGoogle Scholar
  37. Van Noorden CJ, Vogels IM. A sensitive cytochemical staining method for glucose-6-phosphate dehydrogenase activity in individual erythrocytes. II. Further improvements of the staining procedure and some observations with glucose-6-phosphate dehydrogenase deficiency. Br J Haematol. 1985;60:57–63.PubMedCrossRefGoogle Scholar
  38. World Health Organization. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1967;366:1–53.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • J. Kevin Baird
    • 1
    • 2
  • Ari W. Satyagraha
    • 3
  • Germana Bancone
    • 2
    • 4
  1. 1.Eijkman-Oxford Clinical Research UnitJakartaIndonesia
  2. 2.The Centre for Tropical Medicine, Nuffield Department of MedicineUniversity of OxfordOxfordUnited Kingdom
  3. 3.Eijkman Institute for Molecular BiologyJakartaIndonesia
  4. 4.Mahidol-Oxford Research Unit, Faculty of MedicineShoklo Malaria Research UnitMae SotThailand